Back to results
US 2006/0189613 A1Published application
Sulphonamide Compounds that Modulate Chemokine Receptor Activity (CCR4)
OwnerDavid CHESHIREinventor
Life of this patent
Estimating the term…
Abstract
The invention provides pyrimidine, pyridazine and triazine compounds for use in therapy.
Claims16
A compound of formula (I) and pharmaceutically acceptable salts or solvates thereof:
- in which:
- Ar1 is dichlorophenyl or thienyl substituted by one or two chlorine atoms;
- A is a pyrimidine, pyridazine or 1,2,4-triazine ring, each of which can be optionally substituted by one or more groups selected from hydroxyl, halogen, cyano, C1-6alkyl, C1-6alkoxy or C3-6cycloalkyl where in each case the alkyl group may be substituted with 1-3 fluorine atoms, a cyano group or a hydroxy group;
- R1 is C1-6alkyl or C3-6cycloalkyl each of which can be optionally substituted with 1-3 fluorine atoms or a cyano group or R1 is C3-6alkenyl or C3-6alkynyl or C1-6alkyl-R2
- R2 is an aryl group or a 5-7 membered heteroaromatic ring containing 1-4 heteroatoms selected from nitrogen, oxygen or sulphur each of which can be optionally substituted by 1-3 groups selected from halogen, C1-6alkyl, C1-6alkoxy, ═O, ═S, CN or (CH2)nOH where n is 1 or 2.
2 more elements
8-9. (canceled)
A method of treating a CCR4 mediated disease, the method comprising administering to a patient a therapeutically effective amount of a compound of formula (I).
Dependencies are inferred from the claim text.